As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
26 Analysts have issued a Arvinas, Inc. forecast:
26 Analysts have issued a Arvinas, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 312 312 |
10%
10%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -99 -99 |
83%
83%
|
|
| EBIT (Operating Income) EBIT | -102 -102 |
83%
83%
|
|
| Net Profit | -58 -58 |
89%
89%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
| Head office | United States |
| CEO | John Houston |
| Employees | 430 |
| Founded | 2013 |
| Website | www.arvinas.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


